Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 529
Filter
1.
Allergy ; 72(9): 1327-1337, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28213886

ABSTRACT

BACKGROUND: Asthma is a complex lung disease resulting from the interplay of genetic and environmental factors. To understand the molecular changes that occur during the development of allergic asthma without genetic and environmental confounders, an experimental model of allergic asthma in mice was used. Our goals were to (1) identify changes at the small molecule level due to allergen exposure, (2) determine perturbed pathways due to disease, and (3) determine whether small molecule changes correlate with lung function. METHODS: In this experimental model of allergic asthma, matched bronchoalveolar lavage (BAL) fluid and plasma were collected from three groups of C57BL6 mice (control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6 hour, 24 hour, and 48 hour after the last challenge. Samples were analyzed using liquid chromatography-mass spectrometry-based metabolomics. Airway hyper-responsiveness (AHR) measurements and differential cell counts were performed. RESULTS: In total, 398 and 368 dysregulated metabolites in the BAL fluid and plasma of sensitized and challenged mice were identified, respectively. These belonged to four, interconnected pathways relevant to asthma pathogenesis: sphingolipid metabolism (P=6.6×10-5 ), arginine and proline metabolism (P=1.12×10-7 ), glycerophospholipid metabolism (P=1.3×10-10 ), and the neurotrophin signaling pathway (P=7.0×10-6 ). Furthermore, within the arginine and proline metabolism pathway, a positive correlation between urea-1-carboxylate and AHR was observed in plasma metabolites, while ornithine revealed a reciprocal effect. In addition, agmatine positively correlated with lung eosinophilia. CONCLUSION: These findings point to potential targets and pathways that may be central to asthma pathogenesis and can serve as novel therapeutic targets.


Subject(s)
Asthma/metabolism , Metabolic Networks and Pathways/immunology , Animals , Arginine/metabolism , Bronchoalveolar Lavage Fluid , Glycerophospholipids/metabolism , Hypersensitivity/metabolism , Mice , Mice, Inbred C57BL , Nerve Growth Factors/metabolism , Proline/metabolism , Sphingolipids/metabolism
2.
Allergy ; 71(11): 1561-1574, 2016 11.
Article in English | MEDLINE | ID: mdl-27059534

ABSTRACT

BACKGROUND: Signaling through histamine receptors on dendritic cells (DCs) may be involved in the effector phase of peanut-induced intestinal anaphylaxis. OBJECTIVES: The objective of this study was to determine the role of histamine H1 (H1R) and H4 receptors (H4R) in intestinal allergic responses in a model of peanut allergy. METHODS: Balb/c mice were sensitized and challenged with peanut. During the challenge phase, mice were treated orally with the H1R antagonist, loratadine, and/or the H4R antagonist, JNJ7777120. Bone marrow-derived DCs (BMDCs) were adoptively transferred to nonsensitized WT mice. Symptoms, intestinal inflammation, and mesenteric lymph node and intestine mucosal DCs were assessed. Effects of the drugs on DC chemotaxis, calcium mobilization, and antigen-presenting cell function were measured. RESULTS: Treatment with loratadine or JNJ7777120 individually partially suppressed the development of diarrhea and intestinal inflammation and decreased the numbers of DCs in the mesenteric lymph nodes and lamina propria. Combined treatment with both drugs prevented the development of diarrhea and intestinal inflammation. In vitro, the combination suppressed DC antigen-presenting cell function to T helper cells and DC calcium mobilization and chemotaxis to histamine. CONCLUSION: Blockade of both H1R and H4R in the challenge phase had additive effects in preventing the intestinal consequences of peanut sensitization and challenge. These effects were mediated through the limitation of mesenteric lymph node and intestinal DC accumulation and function. Identification of this histamine H1R/H4R-DC-CD4+ T-cell axis provides new insights into the development of peanut-induced intestinal allergic responses and for prevention and treatment of peanut allergy.


Subject(s)
Allergens/immunology , Anaphylaxis/immunology , Arachis/adverse effects , Dendritic Cells/drug effects , Dendritic Cells/immunology , Histamine Antagonists/pharmacology , Histamine H1 Antagonists/pharmacology , Peanut Hypersensitivity/immunology , Receptors, Histamine H4/antagonists & inhibitors , Adoptive Transfer , Anaphylaxis/drug therapy , Anaphylaxis/metabolism , Anaphylaxis/pathology , Animals , Antigen-Presenting Cells/drug effects , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Calcium/metabolism , Cell Lineage , Chemotaxis/drug effects , Chemotaxis/immunology , Cytokines/metabolism , Disease Models, Animal , Female , Intestinal Mucosa/cytology , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Mice , Peanut Hypersensitivity/drug therapy , Peanut Hypersensitivity/metabolism , Peanut Hypersensitivity/pathology , Th17 Cells/drug effects , Th17 Cells/immunology , Th17 Cells/metabolism , Th2 Cells/drug effects , Th2 Cells/immunology , Th2 Cells/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism
3.
N Engl J Med ; 374(11): 1032-1043, 2016 Mar 17.
Article in English | MEDLINE | ID: mdl-26981933

ABSTRACT

BACKGROUND: Common variable immunodeficiency (CVID) is characterized by late-onset hypogammaglobulinemia in the absence of predisposing factors. The genetic cause is unknown in the majority of cases, and less than 10% of patients have a family history of the disease. Most patients have normal numbers of B cells but lack plasma cells. METHODS: We used whole-exome sequencing and array-based comparative genomic hybridization to evaluate a subset of patients with CVID and low B-cell numbers. Mutant proteins were analyzed for DNA binding with the use of an electrophoretic mobility-shift assay (EMSA) and confocal microscopy. Flow cytometry was used to analyze peripheral-blood lymphocytes and bone marrow aspirates. RESULTS: Six different heterozygous mutations in IKZF1, the gene encoding the transcription factor IKAROS, were identified in 29 persons from six families. In two families, the mutation was a de novo event in the proband. All the mutations, four amino acid substitutions, an intragenic deletion, and a 4.7-Mb multigene deletion involved the DNA-binding domain of IKAROS. The proteins bearing missense mutations failed to bind target DNA sequences on EMSA and confocal microscopy; however, they did not inhibit the binding of wild-type IKAROS. Studies in family members showed progressive loss of B cells and serum immunoglobulins. Bone marrow aspirates in two patients had markedly decreased early B-cell precursors, but plasma cells were present. Acute lymphoblastic leukemia developed in 2 of the 29 patients. CONCLUSIONS: Heterozygous mutations in the transcription factor IKAROS caused an autosomal dominant form of CVID that is associated with a striking decrease in B-cell numbers. (Funded by the National Institutes of Health and others.).


Subject(s)
B-Lymphocytes , Common Variable Immunodeficiency/genetics , Ikaros Transcription Factor/genetics , Mutation , Adolescent , Adult , Antigens, CD/analysis , Bone Marrow/immunology , Bone Marrow Examination , Child , Child, Preschool , Chromosomes, Human, Pair 7 , Common Variable Immunodeficiency/immunology , Exome , Female , Heterozygote , Humans , Immunoglobulin G/blood , Lymphocyte Count , Male , Pedigree , Sequence Analysis, DNA/methods
5.
Clin Exp Allergy ; 44(8): 1076-82, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24456221

ABSTRACT

BACKGROUND: Prostaglandin D2 (PGD2 ) plays an important role in allergic inflammation. The PGD2 receptor, CRTH2, is expressed on basophils, eosinophils, and Th2 lymphocytes and mediates chemotactic activity. OBJECTIVE: To define the role of CRTH2 in allergen-induced nasal responses in a mouse model of allergic rhinitis (AR), a potent, selective CRTH2 receptor antagonist, ARRY-063 was administered in a model of allergic rhinitis in mice. METHODS: ARRY-063 was administered orally to ovalbumin (OVA) sensitized and challenged mice. To assess nasal obstruction, respiratory frequency (RF) was monitored by whole-body plethysmography immediately after the 4th challenge (early-phase response, EPR) and 24 h after the 6th challenge (late-phase response, LPR). Nasal resistance (RNA ) was also measured in the LPR. PGD2 was administered with or without OVA to determine the effect of PGD2 on nasal responsiveness. Cytokine levels and histopathological changes in nasal tissue were analysed. RESULTS: Instillation of PGD2 in the nose of sensitized mice together with a low concentration of OVA induced both an EPR and LPR. Treatment with the CRTH2 receptor antagonist prevented the decreases in RF seen immediately following the 4th challenge of sensitized mice (EPR). In the LPR, decreases in RF and increases in RNA were also prevented by antagonist treatment associated with reduced cytokine levels and inflammation in nasal tissues. CONCLUSIONS: These data identify PGD2 as a mediator of both the EPR and LPR in this model of AR and suggest that antagonism of CRTH2 prevents the development of both the EPR and LPR as well as nasal inflammation.


Subject(s)
Nasal Mucosa/immunology , Nasal Mucosa/metabolism , Prostaglandin D2/metabolism , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Allergens/immunology , Animals , Disease Models, Animal , Eosinophils/immunology , Female , Mice , Nasal Mucosa/drug effects , Nasal Mucosa/pathology , Prostaglandin D2/administration & dosage , Rhinitis, Allergic/drug therapy , Rhinitis, Allergic/immunology , Rhinitis, Allergic/metabolism
6.
Allergy ; 68(5): 666-73, 2013.
Article in English | MEDLINE | ID: mdl-23573812

ABSTRACT

BACKGROUND: The role of CD8 T lymphocytes in the pathogenesis of asthma is not well understood. We investigated whether a subset of IL-13-producing BLT1-positive CD8 T lymphocytes are present in asthmatic airways and are associated with impaired lung function. METHODS: Bronchoalveolar lavage (BAL) cells were obtained from asthmatic (n = 39) and healthy control (n = 28) subjects. Cells were stimulated with phorbol ester and ionomycin in the presence of brefeldin A and stained for CD8, BLT1, and intracellular IL-13. The frequency of IL-13-producing BLT1-positive CD8 T lymphocytes was compared between the two groups and related to lung function, serum IgE levels, and reticular basement membrane (RBM) thickness. RESULTS: A subset of CD8 T lymphocytes expressing BLT1 and producing IL-13 were detected in the airways of all asthmatic subjects. The frequency of this subset among recovered lymphocytes was significantly higher in the airways of asthmatic subjects compared with controls (mean ± SEM: 16.2 ± 1.4 vs 5.3 ± 0.5, respectively, P < 0.001) and correlated positively with serum IgE levels and RBM thickness. More importantly, the frequency of CD8 T lymphocytes co-expressing BLT1 and IL-13 was inversely related to FEV1 and FEF[25-75] percent predicted values (P < 0.001). CONCLUSIONS: A subset of CD8 T lymphocytes expressing BLT1 and producing IL-13 is present in the airways of asthmatics. The accumulation of these cells is associated with airway obstruction, suggesting that they may play a significant pathogenic role in bronchial asthma.


Subject(s)
Airway Obstruction/immunology , Airway Obstruction/metabolism , Asthma/immunology , Asthma/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Interleukin-13/biosynthesis , Receptors, Leukotriene B4/metabolism , Adolescent , Adult , Asthma/physiopathology , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Case-Control Studies , Female , Humans , Male , Middle Aged , Respiratory Function Tests , Young Adult
7.
Br J Pharmacol ; 160(6): 1399-407, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20590630

ABSTRACT

BACKGROUND AND PURPOSE: Montelukast and S-carbocysteine have been used in asthmatic patients as an anti-inflammatory or mucolytic agent respectively. S-carbocysteine also exhibits anti-inflammatory properties. EXPERIMENTAL APPROACH: Ovalbumin (OVA) sensitized BALB/c mice were challenged with OVA for 3 days followed by single OVA re-challenge (secondary challenge) 2 weeks later. Forty-eight hours after secondary challenge, mice were assessed for airway hyperresponsiveness (AHR) and cell composition in bronchoalveolar lavage (BAL) fluid. Suboptimal doses of 10 mg.kg(-1) of S-carbocysteine by intraperitoneal injection (ip), 20 mg.kg(-1) of montelukast by gavage, the combination of S-carbocysteine and montelukast or 3 mg.kg(-1) of dexamethasone as a control were administered from 1 day before the secondary challenge to the last experimental day. Isolated lung cells were cultured with OVA and montelukast to determine the effects on cytokine production. KEY RESULTS: Treatment with S-carbocysteine or montelukast reduced both AHR and the numbers of eosinophils in BAL fluid. Neutralizing IFN-gamma abolished the effects of S-carbocysteine on these airway responses. Combination of the two drugs showed further decreases in both AHR and eosinophils in the BAL fluid. Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment. Conversely, S-carbocysteine increased Th1-type cytokines, IFN-gamma and IL-12 in BAL fluid. CONCLUSIONS AND IMPLICATIONS: The combination of two agents, montelukast and S-carbocysteine, demonstrated additive effects on AHR and airway inflammation in a secondary allergen model most likely through independent mechanisms of action.


Subject(s)
Acetates/pharmacology , Bronchial Hyperreactivity/drug therapy , Carbocysteine/pharmacology , Quinolines/pharmacology , Acetates/administration & dosage , Animals , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/pharmacology , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Bronchial Hyperreactivity/immunology , Bronchoalveolar Lavage Fluid , Carbocysteine/administration & dosage , Cyclopropanes , Dexamethasone/pharmacology , Drug Synergism , Drug Therapy, Combination , Eosinophils/metabolism , Female , Inflammation/drug therapy , Inflammation/immunology , Injections, Intraperitoneal , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Quinolines/administration & dosage , Sulfides
8.
Clin Exp Allergy ; 40(8): 1163-74, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20545703

ABSTRACT

BACKGROUND: A novel nutritional formula (NNF) enriched in eicosapentaenoic (EPA) and gamma-linolenic fatty acids and antioxidants reduces airway inflammation and improves clinical outcomes in critically ill patients, but NNF has not been evaluated in chronic inflammatory diseases such as persistent asthma. OBJECTIVE: To evaluate the efficacy, compliance, and safety of NNF in asthmatic children. METHODS: Children, 6-14 years of age, with mild to moderate persistent asthma, on as needed albuterol alone, were randomized to receive daily NNF (n=23) or control formula (n=20) for 12 weeks, with multiple assessments of asthma control, spirometry, measures of airway inflammation, formula tolerance, and adverse events. RESULTS: Daily consumption of either NNF or a control formula showed improvement in asthma-free days over time (P=0.04) but there was no difference between groups. However, the NNF group had lower exhaled nitric oxide levels compared with the control group at weeks 4, 8, and 12 (P<0.05). An overall group difference in log FEV1 PC20 (P=0.05) was found in favour of the NNF group as well. Significantly higher levels of EPA in plasma (P<0.01) and peripheral blood mononuclear cell (PBMC) (P<0.01) phospholipids in the NNF group compared with control group within 2 weeks indicated good adherence with daily NNF intake. There were no differences in adverse events for NNF vs. control after 12 weeks. CONCLUSIONS: Both NNF and control groups demonstrated improvement in asthma-free days. NNF-treated group had reduced biomarkers of disease activity. Rapid PBMC fatty acid composition changes reflected an anti-inflammatory profile. Dietary supplementation with NNF was safe and well tolerated (ClinicalTrials.gov number NCT01087710).


Subject(s)
Antioxidants/therapeutic use , Asthma/diet therapy , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/therapeutic use , Adolescent , Child , Dietary Supplements , Female , Humans , Male , Respiratory Function Tests
9.
Clin Exp Allergy ; 40(2): 317-26, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20015276

ABSTRACT

BACKGROUND: ONO-1301 is a novel drug that acts as a prostacyclin agonist with thromboxane A(2) (TxA(2)) synthase inhibitory activity. We investigated the effect of ONO-1301 on development of airway allergic inflammation. METHODS: Mice sensitized and challenged to ovalbumin (OVA) received ONO-1301, OKY-046 (TxA(2) synthase inhibitor), beraprost, a prostacyclin receptor (IP) agonist, ONO-1301 plus CAY10449 (selective IP antagonist) or vehicle during the challenge period. Twenty-four hours after the OVA challenge, airway hyperresponsiveness (AHR) to methacholine was assessed and bronchoalveolar lavage was performed. Lung specimens were excised for goblet cell staining and analysis of lung dendritic cells (DCs). Bone marrow-derived dendritic cells (BMDCs) were generated, in the presence or absence of drugs, for analysis of DC function. RESULTS: Mice that received ONO-1301 showed significantly lower AHR, airway eosinophilia, T-helper type 2 cytokine levels, mucus production and lung DCs numbers than vehicle-treated mice. These effects of ONO-1301 were mostly reversed by CAY10449. BMDCs treated with ONO-1301 alone showed lower DC functions, such as expression of costimulatory factors or stimulation to spleen T cells. CONCLUSIONS: These data suggest that ONO-1301 may suppress AHR and airway allergic inflammation through modulation of DCs, mainly mediated through the IP receptor. This agent may be effective as an anti-inflammatory drug in the treatment of asthma.


Subject(s)
Bronchial Hyperreactivity/drug therapy , Epoprostenol/agonists , Inflammation/drug therapy , Pyridines/pharmacology , Pyridines/therapeutic use , Thromboxane-A Synthase/antagonists & inhibitors , Thromboxanes/antagonists & inhibitors , Animals , Bronchial Hyperreactivity/chemically induced , Bronchial Hyperreactivity/physiopathology , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Disease Models, Animal , Epoprostenol/administration & dosage , Epoprostenol/analogs & derivatives , Epoprostenol/chemistry , Epoprostenol/pharmacology , Epoprostenol/therapeutic use , Female , Methacrylates/administration & dosage , Methacrylates/chemistry , Methacrylates/pharmacology , Methacrylates/therapeutic use , Mice , Mice, Inbred BALB C , Ovalbumin/administration & dosage , Ovalbumin/adverse effects , Pyridines/administration & dosage , Pyridines/chemistry
10.
Anat Rec (Hoboken) ; 292(7): 1045-61, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19484746

ABSTRACT

Chronic lung disease (CLD) affects premature newborns requiring supplemental oxygen and results in impaired lung development and subsequent airway hyperreactivity. We hypothesized that the maintenance of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling is important for normal lung morphogenesis and treatment with PPARgamma agonists could protect against CLD and airway hyperreactivity (AHR) following chronic hyperoxic exposure. This was tested in an established hyperoxic murine model of experimental CLD. Newborn mice and mothers were exposed to room air (RA) or moderate hyperoxia (70% oxygen) for 10 days and fed a standard diet or chow impregnated with the PPARgamma agonist rosiglitazone (ROSI) for the duration of study. Following hyperoxic exposure (HE) animals were returned to RA until postnatal day (P) 13 or P41. The accumulation of ROSI in neonatal and adult tissue was confirmed by mass spectrometry. Analyses of body weight and lung histology were performed on P13 and P41 to localize and quantitate PPARgamma expression, determine alveolar and microvessel density, proliferation and alpha-smooth muscle actin (alpha-SMA) levels as a measure of myofibroblast differentiation. Microarray analyses were conducted on P13 to examine transcriptional changes in whole lung. Pulmonary function and airway responsiveness were analyzed at P55. ROSI treatment during HE preserved septation and vascular density. Key array results revealed ontogeny groups differentially affected by hyperoxia including cell cycle, angiogenesis, matrix, and muscle differentiation/contraction. These results were further confirmed by histological evaluation of myofibroblast and collagen accumulation. Late AHR to methacholine was present in mice following HE and attenuated with ROSI treatment. These findings suggest that rosiglitazone maintains downstream PPARgamma effects and may be beneficial in the prevention of severe CLD with AHR.


Subject(s)
Lung Diseases/drug therapy , Lung/drug effects , Neovascularization, Physiologic/drug effects , PPAR gamma/agonists , Respiratory System/drug effects , Animals , Animals, Newborn , Bronchoconstriction/drug effects , Bronchoconstriction/physiology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Disease Models, Animal , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Hyperoxia/physiopathology , Infant, Newborn , Infant, Newborn, Diseases/drug therapy , Infant, Newborn, Diseases/metabolism , Infant, Newborn, Diseases/physiopathology , Lung/growth & development , Lung/physiopathology , Lung Diseases/physiopathology , Mice , Mice, Inbred C57BL , Muscle, Smooth/drug effects , Muscle, Smooth/growth & development , Muscle, Smooth/metabolism , Neovascularization, Physiologic/physiology , PPAR gamma/metabolism , Respiratory System/growth & development , Respiratory System/physiopathology , Rosiglitazone , Thiazolidinediones/pharmacology , Thiazolidinediones/therapeutic use , Treatment Outcome , Vasodilator Agents/pharmacology , Vasodilator Agents/therapeutic use
11.
Bone Marrow Transplant ; 43(3): 217-21, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18794870

ABSTRACT

Genetic mutations of proteins regulating nuclear factor of kappa-light polypeptide gene enhancer in B lymphocyte (NF-kappaB) activation result in heritable diseases of development and immunity. Hypomorphic, X-linked mutations in the IKBKG gene (NF-kappaB essential modulator (NEMO) protein), and hypermorphic, autosomal dominant mutations in the IKBA gene (inhibitor of NF-kappaB (IkappaB)-alpha protein), are associated with a phenotype of immune deficiency and often ectodermal dysplasia (ED-ID). ED-ID predisposes patients to recurrent and life-threatening infections and is typically fatal within the first few years of life. Allogeneic hematopoietic SCT (HSCT) may correct the immune deficiency associated with NEMO or IkappaBalpha mutations, but there is very little published data. We gathered clinical data on three ED-ID patients that had undergone HSCT. Conditioning regimens were variable, as were the stem cell sources. All three patients experienced engraftment difficulties as well as post transplant complications. These cases suggest that patients with immune deficiencies caused by NEMO or IkappaBalpha mutations may have intrinsic barriers to successful engraftment, which require further investigation.


Subject(s)
Ectodermal Dysplasia/therapy , Hematopoietic Stem Cell Transplantation/methods , Immunologic Deficiency Syndromes/therapy , Child, Preschool , Ectodermal Dysplasia/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunologic Deficiency Syndromes/immunology , Infant , Infant, Newborn , Retrospective Studies , Transplantation Conditioning
12.
Eur Respir J ; 31(4): 773-82, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18094004

ABSTRACT

Mast cells are thought to contribute to allergic airway disease. However, the role of mast cell-produced mediators, such as tumour necrosis factor (TNF), for the development of allergic airway disease is unclear. In order to define the role of mast cells in acute allergic airway disease two strains of mast cell-deficient mice (Kit(W/Wv) and Kit(W-sh/W-sh)) were studied. Compared with their wild-type littermates, Kit(W/Wv) and Kit(W-sh/W-sh) mice developed significantly lower airway responsiveness to methacholine and less airway inflammation and goblet cell metaplasia, following sensitisation in the absence of adjuvant and airway challenge. Transfer of bone marrow-derived mast cells (BMMCs) from wild-type mice to Kit(W-sh/W-sh) mice reconstituted both airway responsiveness and inflammation to levels similar to those in sensitised and challenged wild-type mice. In contrast, sensitised Kit(W-sh/W-sh) mice reconstituted with BMMCs from TNF-deficient mice were still severely impaired in their ability to develop airway hyperresponsiveness, inflammation or goblet cell metaplasia following allergen challenge. The present results demonstrate the significance of mast cells in the development of airway disease and highlight the importance of mast cell-derived tumour necrosis factor in these responses.


Subject(s)
Asthma/immunology , Mast Cells/immunology , Tumor Necrosis Factor-alpha/immunology , Allergens/immunology , Animals , Bronchial Hyperreactivity/immunology , Disease Models, Animal , Goblet Cells/immunology , Goblet Cells/pathology , Immunization , Inflammation/pathology , Mice , Mice, Knockout , Tumor Necrosis Factor-alpha/metabolism
13.
J Intern Med ; 262(1): 59-77, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17598815

ABSTRACT

Myocardial infarction (MI) is a common clinical diagnosis, associated with significant morbidity and mortality, not only in the short term, but also years following the index event. A more complete understanding of the pathophysiology of MI has ushered the era of multipronged treatment approach, with a combination of goal-directed revascularization, a broad adjunctive pharmacological therapy and aggressive secondary prevention measures. The goals of this article are to review the basic pathophysiological processes, which lead up to a clinical diagnosis of MI, to highlight the essential elements of clinical presentation and to summarize the evidence for comprehensive therapy. Emphasis has been placed on the choice of primary reperfusion therapy for ST-elevation MI, on risk-stratification of patients with non-ST elevation MI, and on rationale behind the selection of anti-ischaemic and antithrombotic therapy. Finally, evidence-based approach to secondary prevention is outlined.


Subject(s)
Myocardial Infarction/therapy , Angioplasty, Balloon, Coronary/methods , Humans , Myocardial Infarction/diagnosis , Myocardial Infarction/physiopathology , Myocardial Reperfusion/methods , Thrombolytic Therapy/methods
15.
Eur Respir J ; 26(4): 577-85, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16204586

ABSTRACT

S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined. In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5-100 mg.kg-1) was administered from 2 days before the secondary challenge through to the day of assay. Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-gamma, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected. In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Bronchial Hyperreactivity/drug therapy , Bronchial Hyperreactivity/immunology , Carbocysteine/therapeutic use , Allergens/adverse effects , Animals , Anti-Inflammatory Agents/immunology , Bronchoalveolar Lavage Fluid/chemistry , Carbocysteine/immunology , Cytokines/analysis , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Ovalbumin/adverse effects
16.
Clin Exp Immunol ; 141(2): 223-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15996186

ABSTRACT

Histological data show perivascular recruitment of inflammatory cells in lung inflammation. However, the process of perivascular inflammation is yet-to-be characterized in any systematic manner at cell and molecular levels. Therefore, we investigated impact of genetic background on perivascular inflammation in acute or chronic airway inflammation in different strains of mice. Further, to address molecular mechanisms of perivascular inflammation, we examined immunohistochemical expression of vascular adhesion protein-1 (VAP-1) in chronic airway inflammation. Histological scoring revealed time and strain specific differences in perivascular recruitment of inflammatory cells in chronic and acute airway inflammation (P < 0.05). The data show that A/J strain is significantly more susceptible for perivascular inflammation followed by BALB/c and C57BL/6, while C3H/HeJ strain showed no perivascular accumulation of inflammatory cells. Of the two strains examined for perivascular inflammation in acute airway inflammation, BALB/c showed more accumulation of inflammatory cells compared to C57BL/c. VAP-1 expression occurred in the endothelium of pulmonary arteries but not in alveolar septa or airways in the control as well as challenged mice. In the inflamed lungs from A/J mice, the VAP-1 staining in pulmonary arteries was more intense compared to the other strains. VAP-1 staining was generally observed throughout the pulmonary arterial wall in chronic lung inflammation. These data show that periarterial inflammation is influenced by the genetic background, and may be partially regulated by VAP-1.


Subject(s)
Genetic Predisposition to Disease , Respiratory Hypersensitivity/genetics , Acute Disease , Amine Oxidase (Copper-Containing)/metabolism , Animals , Cell Adhesion Molecules/metabolism , Chronic Disease , Disease Models, Animal , Mice , Mice, Inbred A , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Respiratory Hypersensitivity/metabolism , Respiratory Hypersensitivity/pathology , Species Specificity
18.
Article in English | MEDLINE | ID: mdl-16869783

ABSTRACT

We have developed methods for the automation of transfection-grade DNA preparation, high-throughput retroviral preparation, and highly parallel phenotypic screens to establish approaches that will allow investigators to examine in an unbiased manner the roles of proteins in mammalian cells. These methods have been used to raise or lower the levels of individual kinases in individual micro-well cultures either by cDNA or short hairpin RNA expression and will allow investigators to treat mammalian cells in culture in manners that are analogous to genetic screens in yeast. Our proof-of-principle experiments have been performed in human cells using repositories that represent over 75% of the protein, nucleotide, carbohydrate, lipid, and amino acid kinases in the human genome. These initial experiments have demonstrated the feasibility of two general types of screens. We have performed phenotypic screens to identify proteins with specific roles in a chosen function and genetic interaction screens to establish epistatic relations between different proteins. The results suggest that any phenotype that can be scored by a robust assay in tissue culture is amenable to these types of screens and that interactions between mammalian proteins can be established. These results point to the near-term goal of establishing comprehensive, unbiased screens that will allow queries on the roles of all human proteins.


Subject(s)
DNA, Complementary/genetics , RNA Interference , Carcinoma, Non-Small-Cell Lung/enzymology , Carcinoma, Non-Small-Cell Lung/genetics , Cell Line, Tumor , Cells, Cultured , Gene Expression , Genetic Testing , Genomics , Humans , Lung Neoplasms/enzymology , Lung Neoplasms/genetics , Phenotype , Phosphotransferases/genetics , Retroviridae/genetics , Suppression, Genetic , Transfection
19.
Clin Exp Allergy ; 35(12): 1521-34, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16393317

ABSTRACT

Airway inflammation is a characteristic feature of allergic asthma. Central to the initiation and progression of the inflammatory process are allergen-specific T lymphocytes that attract eosinophils, mast cells, and B cells to the airways by the secretion of specific cytokines. The direction of T cell responses is influenced by co-stimulatory signals that modulate the antigen-specific signal delivered by the T cell receptor. In addition to the prototypic co-stimulatory molecule, CD28, a number of newly identified co-stimulatory molecules and their ligands have now been characterized. Over the past 5 years, the role of these molecules in the pathophysiology of allergen-mediated sensitization and airway inflammation has been extensively studied in animal models of allergic asthma. The aim of this review is to provide a detailed overview on recent studies in mice and preliminary findings in man and to discuss the potential therapeutic and preventive treatment strategies offered by interactions with co-stimulatory molecules for patients with allergic airway diseases.


Subject(s)
Antigens, CD/immunology , Asthma/immunology , Asthma/therapy , Cytokines/immunology , T-Lymphocytes/immunology , Animals , Antigens, Differentiation, T-Lymphocyte/immunology , Bronchial Hyperreactivity , CD28 Antigens/immunology , Humans , Inducible T-Cell Co-Stimulator Protein , Ligands , Lymphocyte Activation , Mice , Mice, Inbred Strains , Mice, Knockout , Models, Animal
SELECTION OF CITATIONS
SEARCH DETAIL
...